Peptide Library

Newest Peptide Protocols

5-Amino-1MQ Protocol: How to Cycle It, Timing & What to Expect

A 5-Amino-1MQ cycle typically runs four to six weeks at a once or twice daily frequency, followed by a two to four week off-cycle break that allows the metabolic pathway to reset before the next round. The cycle opens with a brief one to two day tolerance-establishing phase, then settles into a steady maintenance pattern for the remainder. Because the dose depends heavily on which delivery route you use, your goal, and how your body responds to NNMT inhibition, the personalized dose is built in the MyPeptidePal Protocol Creator rather than stated here.

Bioglutide Protocol: How to Cycle It, Timing & What to Expect

A Bioglutide protocol runs as a continuous daily oral capsule with a gradual escalation phase over the first several weeks into a steady maintenance phase, with no structured off-cycle break. Phase 2 trials ran the protocol continuously for 13 weeks, and the general horizon for meaningful metabolic progress is 20 to 24 weeks of consistent daily use. Because this is a continuous-use metabolic compound rather than a cycle-and-rest peptide, any discontinuation is tapered rather than abrupt. The personalized dose within that escalation arc depends on your goal, your tolerance at each step, and your clinical context, and is built in the MyPeptidePal app.

Gotratix A18 Protocol: How to Cycle It, Timing & What to Expect

A gotratix A18 protocol runs as a defined course rather than continuous daily use: either a focused 10-day short course or a fuller 30-day course, followed by an off-cycle break of two to six months. The compound is taken orally as a capsule or sublingually as drops before meals, never injected, and where someone lands within the dose range depends on their goal, chosen format, and how frequently courses are repeated across the year. This guide covers the full cycle structure, timing principles, what to expect across the arc of a well-run protocol, and the most common mistakes people make, while the personalized dose and exact cycle structure are built in the MyPeptidePal Protocol Creator.

NMN Protocol: How to Cycle It, Timing & What to Expect

An NMN protocol is built around daily oral supplementation taken every morning, with meaningful results assessed after eight to twelve weeks of consistent use. The cycle does not require a traditional loading phase, and off-cycle breaks are optional rather than clinically mandated. Your exact dose depends on your goal, your age, and how your body responds, and it is built in the MyPeptidePal Protocol Creator rather than fixed here.

NMNH Protocol: How to Cycle It, Timing & What to Expect

An NMNH protocol runs as a continuous daily oral cycle of 90 days, taken once each morning at a consistent dose with no loading phase and no mandated off-cycle break. The dose is shaped by your goal, your prior experience with NAD+ precursors, and whether you are new to NMNH or transitioning from a related compound. The exact number is built in the MyPeptidePal Protocol Creator rather than fixed for everyone.

Newest Peptide Guides

Why Peptides Say 'Not for Human Consumption': The Real Reason Behind the Label

Peptides sold online carry "research use only" and "not for human consumption" labels because most popular peptides have not received FDA approval for human use, and the FDA has specifically banned a large number of them from being compounded for patients. Without a legal pathway to sell these compounds as prescription drugs or approved supplements, vendors use research-use-only labeling as the only commercially viable option to put these products on the market. The label is a real regulatory designation with specific legal meaning - and it is also a protective strategy vendors use to avoid FDA enforcement. Understanding both sides of that equation is how the confusing label starts to make sense.

How the FDA's Bulk Peptide Reclassification May Have Been Illegal - And Why It Matters for Your Access

In September 2023, the FDA placed approximately 19 peptides into Category 2 of its compounding bulk drug substance framework - a designation that effectively blocked licensed compounding pharmacies from using them. The problem is that FDA's own administrative guidance requires each substance to be evaluated individually, with a specific balancing test applied to each compound's safety profile and clinical need. Moving roughly 19 chemically distinct substances in a single action may have bypassed that requirement. By 2026, the agency began reversing some of those restrictions and scheduling advisory committee reviews for others - a sequence that regulatory attorneys read as an implicit acknowledgment that the original action was procedurally incomplete.

Research Peptide COAs: What They Really Mean and What to Actually Look For

A Certificate of Analysis for a research peptide is a laboratory report documenting test results for a specific sample from a specific production lot - nothing more, nothing less. In the research peptide market, COAs have been heavily marketed as quality guarantees, but a visually polished COA is not the same thing as a rigorous one. What actually matters is whether an independent, accredited lab tested the specific lot you received for the right analytes - endotoxins, heavy metals, microbial content, TFA residuals, and potency alongside purity and identity - and whether the batch number on that document is traceable to the vials in your hands.

Current Peptide News

When a Vendor's Manufacturing Process Page Is Someone Else's: A Documented Case

Cenexa Labs published a 12-step "Cenexa Pure" manufacturing process page in October 2025. In January 2026, a near-identical 12-step page appeared on the Licensed Peptides website under Licensed Peptides branding. The copy reproduces the original's layout, illustrations and wording, and it carries several spelling errors the original does not have. It also reproduces a badge claiming to be the only US research peptide manufacturer, a claim two companies cannot both hold. The practical lesson for buyers is that a polished peptide vendor manufacturing process page is not, by itself, evidence of a real process.